Insulin-like growth factor (IGF 1), also termed somatomedin C, is a small polypeptide (M.W. 7400 daltons) whose primary physiological role is to act on skeletal development via the endocrine pathway, together with growth hormone (Furnaletto et al., 1977; Zapf & Froesch, 1986) . This factor stimulates the growth of many cell types (Moses & Pilistine, 1985) , including various breast cancer cell lines (Furnaletto & Di Carlo, 1984; Myal et al., 1984; Huff et al., 1986; Dickson & Lippman, 1987 ; Karey & Sirbasku, 1988) . IGFI is synthesised in many tissues (D'Ercole et al., 1984; Murphy et al., 1987; Lund et al., 1986) and immunoreactive IGF1 had been found in the medium conditioned by breast cancer cell lines (Baxter et al., 1983; Huff et al., 1986; Minuto et al., 1987) . The recent demonstration of the absence of IGF1 mRNA in these cells suggests that 'immunoreactive IGF1' represents either IGF1-related proteins or secreted IGF1 binding proteins (Yee et al., 1989) . The presence of IGF1 mRNA in breast cancers evokes a paracrine role of this factor (Yee et al., 1989) .
The first step in IGFI action is its binding to membrane receptors (Rosenfeld & Hintz, 1988 (Furnaletto & Di Carlo, 1984; Myal et al., 1984; De Leon et al., 1988; Pollak et al., 1988; Peyrat et al., 1989) as well as in breast cancers (Peyrat et al., 1988a) or in benign breast diseases (Peyrat et al., 1988b) . We demonstrated that IGF2 was a good competitor of the binding of "251-IGF1 to IGFI-R whereas insulin competed with a potency lower than 1/100th of IGFI's potency.
Chemical cross-linking experiments revealed that the apparent molecular weight of the binding site was 130,000 daltons (Peyrat et al., 1988a) . Therefore, the IGF1 specific binding sites share a close structural homology with insulin receptor and correspond to the previously described type I IGF receptors (IGF1-R) in normal tissues. It has recently been shown that the mitogenic effect of IGF2 on breast cancer epithelial cell lines (Karey & Sirbasku, 1988; Yee et al., 1988) could be mediated, at least partially, by IGFI-R Cullen et al., 1990) .
Several authors have demonstrated that most breast cancers contain IGF1-R (Peyrat et al., 1988a; Pollack et al., 1987; Pekonen, 1988; Foekens et al., 1989) . In our study, the presence of IGF1-R is associated to a better prognosis (Bonneterre et al., 1990) . Conversely, IGF1-R are found less frequently and at lower concentrations in benign breast diseases (Peyrat et al., 1988b (Israel et al., 1984; Bohannon et al., 1986) , the adrenal gland (Shigematsu et al., 1989) and the ovary (Monget et al., 1989) .
We have used this technique to specify the localisation and to quantify high affinity IGFI-R in (Peyrat et al., 1988a) .
Quantitative IGFJ-R autoradiography Frozen sections (7 pm) were processed as previously described (Haour et al., 1987 (1986) and Shigematsu et al. (1989) . Non-specific binding was determined in the presence of 5 x 10-7 M IGF1. In some cases, the competition was achieved with alpha IR3 monoclonal antibody (purchased from Clinisciences, France) that specifically blocks breast cancer IGF1-R (Pollak et al., 1988; Rohlik et al., 1987; . After pre-incubation of cryostat sections in the presence or absence of 10 .g ml-' of alpha IR-3 in Tris-HCl buffer during one hour at room temperature, the 251I-IGFI was added. Following the incubations, the sections were washed three times for 10 min in ice-cold Tris-HCl buffer (50 mM), dried, and exposed for 7 days to Amersham autoradiographic films (3H-hyperfilm). The films were processed and the relative density of'251-IGF1 binding sites was quantified by computerised densitometry using an image analyser (RAG 200, BIOCOM, Les Ulis, France). It was related to the concentration of radioactivity as based on a comparison with standard curves generated by processing sets of Amersham '251-microscale; the results were expressed in femtomoles of ligand bound per milligram of proteins (Israel et al., 1984) . Normal human liver was used as negative control as it is an abundant producer of IGFl binding protein but expresses very little type I IGF receptor.
Biochemical IGFJ receptor assay The frozen tissue was weighed and then pulverised (Spex-Bioblock France). The tissues were homogenised in 20 mM Tris HCI, 3 mM EDTA, 1 mM dithiothreitol, 0.01% azide, pH 7.6. The homogenate was centrifuged at 800g for 10 min. and the supernatant was ultracentrifuged at 105,000 g for 60 min. The supernatant (cytosol) was removed and the pellet ('microsomal' fraction) was resuspended in 25 mm Tris-HCl, 10mM MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, pH 7.6 (Tris-MgCl2 buffer). The protein concentration was determined by the method of Lowry et al. (1951) applied either directly in the cytosol fraction, or after extraction from the membranes (with NaOH 1 N) in the microsomal fraction.
The binding test was described previously (Peyrat et Figure 2a ) and non-specific binding (12.2 fmolesmg-' protein, Figure 2b) Figure 4 shows the correlation between the results obtained, demonstrating a highly significant positive correlation between the two methods. Using the biochemical method we considered that tumours were negative when the specific binding was lower than 1% (Peyrat et al., 1988b) . Using this criterion, six tumours were found to be negative, with the more sensitive autoradiographic method, IGFl specific binding was detectable in the same tumours.
The specific IGFI binding, in the breast cancers, was particularly high and had a wide range in the breast cancers. The median concentration was 30 fmoles mg-' of proteins (50% of values were between 19 and 60 fmoles mg-' of proteins, range 1.9-1!14). It was significantly higher (p < 0.001) than the median concentration in benign disease (0.7 fmoles mg-' of proteins, 50% of values were between 0.5 and 0.9 fmoles mg-' of proteins, range 0-8.6). In the two normal breast tissues studied, the IGFI specific binding was detectable but low (0.8 and 6.2 fmoles mg' of proteins). In the same incubation conditions, the normal human liver, which expresses few IGF1 receptors and was used as negative control, exhibited a '251-IGFI specific binding of 9.36 fmoles mg-' of proteins.
In six cases, IGF1-R were detected both in the breast carcinoma tissue and in the adjacent benign breast disease tissue, demonstrating much lower concentrations in the latter ( Figure 5 ). Interestingly, in most breast carcinomas (15/18) it was possible to detect areas with a significantly high density of labelling. Conversely, in benign breast diseases or normal breast (11/12) the IGF1-R labelling was diffuse and there were no areas with a higher IGFI-R concentration.
Discussion
The specificity of the '25I-IGFl binding determined by HAA, in breast cancer sections, was similar to our previous findings using membrane preparations (Peyrat et al., 1988a We found a significant correlation between IGF1-R histoautoradiographic and biochemical quantifications, demonstrating that it is possible to utilise HAA to assay IGF1-R. Moreover, HAA allows the tissular localisation of IGFI-R in very heterogenous tissue such as breast tumours. IGF1 specific binding is limited to the areas of breast tumours that represent target tissue for IGF1. In fact, HAA demonstrates that specific binding sites are localised on the epithelial component; whereas the stromal tissue as well as the duct lumina contained only unspecifically bound IGFl. Most of the human breast cancers studied exhibited strong IGF1 specific binding. In benign breast diseases, low levels of specific binding were detected either in distrophic diseases, which contain few epithelial cells or in fibroadenomas, which are epithelium-rich tissues. These results suggest that proliferating epithelial cells were labelled by 25I-IGF1; it would be interesting to analyse specific '25I-IGFI binding in epithelial atypical hyperplasia. The concept of the importance of IGF1-R as proliferative marker can be applicable for other tissues like human lung cancers (Shigematsu et al., 1990) , neoplastic endometrium (Talavera et al., 1990) and colon cancer cells (Guo et al., 1990) . We have some results indicating high levels of IGF1-R in neoplastic endometrium, ovaries and liver carcinoma (Figure 4) . HAA also appears to have a potential interest in the analysis of the ontogeny of IGFI binding in relation to the evolution of mastopathy to carcinoma, and also in the receptor quantification in tumours with a limited amount of tissue.
HAA allows precise analysis of the significance of low IGF1-R levels in the tumours. In fact, the low levels could correspond to two contrasting situations: either a diffuse labelling of the tissue (as in benign breast diseases) or a heterogeneous labelling with limited areas containing relatively high IGF1-R concentrations (as is the case for the colloid tumour). It can be proposed that in the latter situation, the tumours would present clusters of epithelial cells containing an appreciable quantity of IGF1 receptors and would develop under IGF1 stimulation. In all cancers considered as negative (<1%) by biochemistry, using HAA we detected very low levels of specific binding (3 fmoles mg-' protein). A detailed analysis of the sections demonstrated that, in these tumours, there were no areas with high IGF1-R concentration. In contrast, we detected by biochemical analysis five breast cancers with low IGF1-R levels (between 1 to 2%); HAA allowed the discrimination of two categories of tumours in this group. In two individual cases, the labelling was diffuse (with 1.8 and 20 fmoles mg-' protein of specific '251I-IGFI binding, respectively) and these tumours could be considered as negative. In other tumours, HAA demonstrated a heterogeneity of specific labelling with clusters of IGF1-R rich cells (with 44.7, 46.5 and 100 fmoles mg-' protein of specific binding in cell clusters respectively) and the tumours were positive. Clearly, the HAA was potent technique to reveal the presence of IGF1-R in tumours and improve the classification of these tumours as IGF1-R negative or positive. We have demonstrated that a poor prognosis is associated with negative, biochemically detected, IGFI-R (Bonneterre et al., 1990) . HAA could be useful for a better selection of IGF1-R negative tumours.
In conclusion, HAA should be highly useful for examining tumour heterogeneity with respect to IGFl-responsiveness. IGF1 is an important growth factor in breast cancer and IGFI-R is a good marker of epithelial proliferation.
